The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS

BMC Research Notes

Pablo Villoslada¹  Bernardo Sanchez-Dalmau²  Albert Saiz³  Irati Zubizarreta¹  Erika Lampert¹  Marc Figueras Roca²  Magi Andorra¹  Ana Tercero³  Sara Llufriu¹  Santiago Ortiz-Pérez²  Ruben Torres-Torres²  Eloy Martínez-Heras¹  Iñigo Gabilondo¹  Elena Fraga-Pumar¹  Elena H Martínez-Lapiscina¹ 

[1] Center of Neuroimmunology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Casanova 145, Planta 3A, 08036 Barcelona, Spain;Department of Ophthalmology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Barcelona, Spain;Department of Neurology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Barcelona, Spain

关键词: Cohort studies;    Neurodegeneration;    Visual pathway;    Multiple Sclerosis;   

Others  :  1092016
DOI  :  10.1186/1756-0500-7-910

 received in 2013-12-13, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

Multiple Sclerosis (MS) is an immune-mediated disease of the Central Nervous System with two major underlying etiopathogenic processes: inflammation and neurodegeneration. The latter determines the prognosis of this disease. MS is the main cause of non-traumatic disability in middle-aged populations.

Findings

The MS-VisualPath Cohort was set up to study the neurodegenerative component of MS using advanced imaging techniques by focusing on analysis of the visual pathway in a middle-aged MS population in Barcelona, Spain. We started the recruitment of patients in the early phase of MS in 2010 and it remains permanently open. All patients undergo a complete neurological and ophthalmological examination including measurements of physical and disability (Expanded Disability Status Scale; Multiple Sclerosis Functional Composite and neuropsychological tests), disease activity (relapses) and visual function testing (visual acuity, color vision and visual field). The MS-VisualPath protocol also assesses the presence of anxiety and depressive symptoms (Hospital Anxiety and Depression Scale), general quality of life (SF-36) and visual quality of life (25-Item National Eye Institute Visual Function Questionnaire with the 10-Item Neuro-Ophthalmic Supplement). In addition, the imaging protocol includes both retinal (Optical Coherence Tomography and Wide-Field Fundus Imaging) and brain imaging (Magnetic Resonance Imaging). Finally, multifocal Visual Evoked Potentials are used to perform neurophysiological assessment of the visual pathway.

Discussion

The analysis of the visual pathway with advance imaging and electrophysilogical tools in parallel with clinical information will provide significant and new knowledge regarding neurodegeneration in MS and provide new clinical and imaging biomarkers to help monitor disease progression in these patients.

【 授权许可】

   
2014 Martínez-Lapiscina et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hauser SL, Oksenberg JR: The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
• [2]Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372:1502-1517.
• [3]Hauser SL, Chan JR, Oksenberg JR: Multiple sclerosis: prospects and promise. Ann Neurol 2013, 74:317-327.
• [4]Filippi M, Rocca MA: MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol 2005, 252(Suppl 5):v16-v24.
• [5]Losy J: Is MS an inflammatory or primary degenerative disease? J Neural Transm 2013, 120:1459-1462.
• [6]Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, Evangelou N: Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010, 16:406-411.
• [7]Chen L, Gordon LK: Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol 2005, 16:315-320.
• [8]Jasse L, Vukusic S, Durand-Dubief F, Vartin C, Piras C, Bernard M, Pelisson D, Confavreux C, Vighetto A, Tilikete C: Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler 2013, 19:1618-1626.
• [9]Castro SM, Damasceno A, Damasceno BP, de Vasconcellos JP, Reis F, Iyeyasu JN, de Carvalho KM: Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis. Arq Neuropsiquiatr 2013, 71:437-441.
• [10]Klistorner A, Garrick R, Barnett MH, Graham SL, Arvind H, Sriram P, Yiannikas C: Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology 2013, 80:242-245.
• [11]Galetta KM, Calabresi PA, Frohman EM, Balcer LJ: Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics 2011, 8:117-132.
• [12]Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A: Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 2012, 18:991-999.
• [13]Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Frohman TC, Newsome S, Ratchford JN, Balcer LJ, Pham DL, Crainiceanu CM, Frohman EM, Reich DS, Calabresi PA: Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol 2013, 70:34-43.
• [14]Ciccarelli O, Toosy AT, Hickman SJ, Parker GJ, Wheeler-Kingshott CA, Miller DH, Thompson AJ: Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp 2005, 25:308-316.
• [15]Sepulcre J, Goni J, Masdeu JC, Bejarano B, Velez de Mendizabal N, Toledo JB, Villoslada P: Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway. Arch Neurol 2009, 66:173-179.
• [16]Reich DS, Smith SA, Gordon-Lipkin EM, Ozturk A, Caffo BS, Balcer LJ, Calabresi PA: Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol 2009, 66:998-1006.
• [17]Kolbe S, Bajraszewski C, Chapman C, Nguyen T, Mitchell P, Paine M, Butzkueven H, Johnston L, Kilpatrick T, Egan G: Diffusion tensor imaging of the optic radiations after optic neuritis. Hum Brain Mapp 2012, 33:2047-2061.
• [18]Villoslada P, Sepulcre J, Toledo J, Bejarano B: Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2008, 71:1747. author reply 1747–1748
• [19]Siger M, Dziegielewski K, Jasek L, Bieniek M, Nicpan A, Nawrocki J, Selmaj K: Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol 2008, 255:1555-1560.
• [20]Summers M, Fisniku L, Anderson V, Miller D, Cipolotti L, Ron M: Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult Scler 2008, 14:197-204.
• [21]Toledo J, Sepulcre J, Salinas-Alaman A, Garcia-Layana A, Murie-Fernandez M, Bejarano B, Villoslada P: Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 2008, 14(7):906-912.
• [22]Saidha S, Omar O, Al-Louzi J, Ratchford , Bhargava P, Oh J, Newsome S, Prince J, Pham D, Roy S, Van Zijl P, Balcer L, Frohman E, Reich D, Crainiceanu C, Calabresi P: Retinal measures reflect global neurodegeneration and inflammation; a 4-year longitudinal study of optical coherence tomography and MRI in MS [abstract]. Mult Scler 2014, 20:Y12.2.
• [23]Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
• [24]Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
• [25]Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A: The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One 2012, 7:e34823.
• [26]Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
• [27]Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E: Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997, 42:379-382.
• [28]Demaree HA, DeLuca J, Gaudino EA, Diamond BJ: Speed of information processing as a key deficit in multiple sclerosis: implications for rehabilitation. J Neurol Neurosurg Psychiatry 1999, 67:661-663.
• [29]Bever CT Jr, Grattan L, Panitch HS, Johnson KP: The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult Scler 1995, 1:165-169.
• [30]Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F, Garcea O, Villoslada P: Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler 2006, 12:187-195.
• [31]Balcer LJ, Baier ML, Pelak VS, Fox RJ, Shuwairi S, Galetta SL, Cutter GR, Maguire MG: New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 2000, 6:163-171.
• [32]Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ: Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005, 64:992-995.
• [33]Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R: Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. J Neurol Sci 2012, 318:119-124.
• [34]Ware JE, Kosinski M, Dewey JE: How to Score Version Two of the SF-36 Health Survey. Lincoln: QualityMetric, Incorporated; 2000.
• [35]Cole BL, Lian KY, Lakkis C: The new Richmond HRR pseudoisochromatic test for colour vision is better than the Ishihara test. Clin Exp Optom 2006, 89:73-80.
• [36]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [37]Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, Osborne LA, Noble JG: A large-scale study of anxiety and depression in people with Multiple Sclerosis: a survey via the web portal of the UK MS Register. PLoS One 2012, 7:e41910.
• [38]Tejero AG, Farré J: Uso clínico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Depto Psiquiatr Fac Med Barna 1986, 13:233-238.
• [39]Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD: Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol 2001, 119:1050-1058.
• [40]Raphael BA, Galetta KM, Jacobs DA, Markowitz CE, Liu GT, Nano-Schiavi ML, Galetta SL, Maguire MG, Mangione CM, Globe DR, Balcer LJ: Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol 2006, 142:1026-1035.
• [41]Balcer LJ, Baier ML, Kunkle AM, Rudick RA, Weinstock-Guttman B, Simonian N, Galetta SL, Cutter GR, Maguire MG: Self-reported visual dysfunction in multiple sclerosis: results from the 25-item national eye institute visual function questionnaire (VFQ-25). Mult Scler 2000, 6:382-385.
• [42]Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, Wilson JA, Maguire MG, Galetta SL, Frohman E, Calabresi PA, Schuman JS, Balcer LJ: Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 2012, 119:1250-1257.
• [43]Cadavid DLN, Costello F, Rahilly A, Klistorner A: Technical feasibility of implementing multifocal VEP for multicenter clinical trials [abstract]. Neurology 2013, 80:IN4-1.004.
• [44]Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J: Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch Neurol 2006, 63:847-850.
• [45]Blanco R, Perez-Rico C, Puertas-Munoz I, Ayuso-Peralta L, Boquete L, Arevalo-Serrano J: Functional assessment of the visual pathway with multifocal visual evoked potentials, and their relationship with disability in patients with multiple sclerosis. Mult Scler 2014, 20:183-191.
• [46]Atkinson A, Mazo C: Imaged Area of the Retina. http://www.optos.com/Global/documents/CaseStudies_ImagedAreaOfTheRetina.pdf webcite
• [47]Mackenzie PJ, Russell M, Ma PE, Isbister CM, Maberley DA: Sensitivity and specificity of the optos optomap for detecting peripheral retinal lesions. Retina 2007, 27:1119-1124.
• [48]Witmer MT, Parlitsis G, Patel S, Kiss S: Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis((R)) noncontact ultra-widefield module versus the Optos((R)) Optomap((R)). Clin Ophthalmol 2013, 7:389-394.
• [49]Serbecic N, Beutelspacher SC, Aboul-Enein FC, Kircher K, Reitner A, Schmidt-Erfurth U: Reproducibility of high-resolution optical coherence tomography measurements of the nerve fibre layer with the new Heidelberg Spectralis optical coherence tomography. Br J Ophthalmol 2011, 95:804-810.
• [50]Pierro L, Gagliardi M, Iuliano L, Ambrosi A, Bandello F: Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments. Invest Ophthalmol Vis Sci 2012, 53:5912-5920.
• [51]Gabilondo I, Martinez-Lapiscina EH, Martinez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P: Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol 2014, 75:98-107.
• [52]Ortiz-Perez S, Martinez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Martinez-Heras E, Saiz A, Sanchez-Dalmau B, Villoslada P: Retinal periphlebitis is associated with multiple sclerosis severity. Neurology 2013, 81:877-881.
• [53]Martinez-Lapiscina EH, Ortiz-Perez S, Fraga-Pumar E, Martinez-Heras E, Gabilondo I, Llufriu S, Bullich S, Figueras M, Saiz A, Sanchez-Dalmau B, Villoslada P: Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 2014, 20:1207-1216.
• [54]Cleary PA, Beck RW, Anderson MM Jr, Kenny DJ, Backlund JY, Gilbert PR: Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 1993, 14:123-142.
• [55]Klistorner A, Arvind H, Nguyen T, Garrick R, Paine M, Graham S, O'Day J, Grigg J, Billson F, Yiannikas C: Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol 2008, 64:325-331.
• [56]Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA: Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005, 236:254-260.
• [57]Sethi V, Yousry TA, Muhlert N, Ron M, Golay X, Wheeler-Kingshott C, Miller DH, Chard DT: Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 2012, 83:877-882.